Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (HEPA) generates news that reflects its transition from liver-focused drug development to diagnostic testing and its evolving capital markets profile. Company announcements describe Hepion as a clinical stage biopharmaceutical firm that had been developing rencofilstat, a cyclophilin inhibitor for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC) and other chronic liver diseases, and that is now concentrating on diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and HCC.
News items for HEPA commonly cover strategic shifts and partnerships, such as Hepion’s license agreement with New Day Diagnostics LLC to in-license diagnostic tests in these areas. Releases also discuss the status of its ASCEND-NASH Phase 2b clinical trial, including the decision to wind down and close the trial, and the subsequent sale of rencofilstat-related patent assets, knowhow and clinical data in exchange for a nominal amount and a contingent value right for stockholders.
Investors following HEPA will also find capital markets and listing updates in the news feed. Hepion has reported a reverse stock split intended to address Nasdaq’s minimum bid price requirement, a public offering of common stock and warrants, and later a delisting notification from Nasdaq citing continued listing standard deficiencies and concerns that the company was a public shell. Subsequent news confirms the suspension of trading on Nasdaq and the transition of HEPA shares to quotation on the OTCQB Venture Market.
The HEPA news stream further includes corporate transaction and governance developments, including the proposed but ultimately terminated merger with Pharma Two B Ltd., the effectiveness and later cancellation of a special stockholder meeting related to that transaction, and leadership changes such as the appointment of an interim Chief Executive Officer and the resignation of a chief financial officer and director. For readers tracking the company’s evolution toward precision diagnostics and its efforts to manage capital and strategic alternatives, the HEPA news page offers an organized view of these disclosures.
Hepion Pharmaceuticals (OTCQB:HEPA), a clinical stage biopharmaceutical company, has announced its successful transition to the OTCQB Venture Market. The company's common stock commenced trading on the OTCQB on June 25, 2025, under the symbol HEPA.
Hepion focuses on developing and commercializing diagnostic tests for multiple conditions including celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori, and hepatocellular carcinoma (HCC).
Hepion Pharmaceuticals (NASDAQ:HEPA) has received a delisting notification from Nasdaq on May 9, 2025. The company's stock will be suspended from trading on Nasdaq effective May 13, 2025, and is expected to transition to trading on the OTC Markets Group under the symbol "HEPA". The delisting is due to two main compliance failures: not maintaining a minimum bid price of $1.00 per share (Rule 5550(a)(2)) and Nasdaq's determination that the company is a public shell (Rule 5101).
Notably, Hepion has undergone a significant business transformation from a clinical stage biopharmaceutical company developing NASH, HCC, and liver disease treatments to becoming a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and HCC.
Hepion Pharmaceuticals (NASDAQ:HEPA) has signed a binding letter of intent with New Day Diagnostics LLC to in-license diagnostic tests for multiple conditions. The agreement covers tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori, and hepatocellular carcinoma (HCC).
The combined addressable market for these diagnostics exceeds $15 billion, with individual markets showing significant growth potential: Respiratory Panel ($5.6B market, 6.6% annual growth), H. pylori detection ($700M market, 6.0% growth), CeliaCare ($457M market, 10.4% growth), and mSEPT9 for HCC ($8.7B market, 6.7% growth). The celiac, respiratory multiplex, and H. pylori tests already have CE marks and can be sold in Europe through New Day's existing distributor network.
Hepion Pharmaceuticals (NASDAQ: HEPA) has announced a 1-for-50 reverse stock split, effective March 17, 2025, at 4:01 p.m. Eastern Time. The company's shares will begin trading on a split-adjusted basis on March 18, 2025, maintaining its NASDAQ symbol 'HEPA' with a new CUSIP number 426897 401.
The reverse split aims to increase the bid price to meet NASDAQ's $1.00 minimum bid requirement for continued listing. This corporate action will reduce outstanding shares from approximately 54.25 million to 1.08 million. Stockholders approved this measure at the annual meeting on March 10, 2025.
The split will automatically combine every 50 shares into one share, with fractional shares rounded up to the next whole share. This action will not affect stockholders' ownership percentages or voting power, except for minimal changes due to fractional share treatment. Proportionate adjustments will be made to stock options, incentive plans, and outstanding warrants.
Hepion Pharmaceuticals (NASDAQ:HEPA) has announced a $9.0 million public offering of 27,692,310 shares of common stock or pre-funded warrants. Each share or warrant comes with two common warrants: a series A and series B, both with an exercise price of $0.40 per share.
The combined offering price is $0.325 per common stock unit and $0.3249 for pre-funded warrant units. The proceeds will be used to repay certain debt and for general corporate purposes, including working capital, operating expenses, and capital expenditures.
The offering, managed by sole placement agent Laidlaw & Company (UK), is expected to close around January 23, 2025. The offering is made pursuant to an effective registration statement on Form S-1 and a related registration statement filed under Rule 462(b).
Hepion Pharmaceuticals (NASDAQ: HEPA) has announced the termination of its merger agreement with Pharma Two B . The merger agreement, which was initially entered into on July 19, 2024, has been mutually terminated with no termination fees required from either party. As a result, Hepion has cancelled its special stockholders meeting scheduled for December 12, 2024, and withdrawn the proposals outlined in its Definitive Proxy Statement filed with the SEC on November 8, 2024.
Hepion Pharmaceuticals (HEPA) has issued a letter to shareholders urging support for its proposed merger with Pharma Two B at the upcoming Special Meeting on December 12, 2024. The company's board unanimously recommends the merger after reviewing strategic alternatives, citing financial challenges and inability to fund clinical development. The merger would allow shareholders to participate in Pharma Two B's late-stage Parkinson's Disease treatment, P2B001. If the merger fails to receive shareholder approval, Hepion warns of potential Nasdaq delisting and bankruptcy risks due to financial resources. While Pharma Two B doesn't plan to advance Hepion's drug pipeline, Hepion remains committed to attempting to monetize its assets for shareholder benefit.
Pharma Two B and Hepion Pharmaceuticals (NASDAQ: HEPA) announced that the SEC has declared effective their merger registration statement on Form F-4. The merger, announced on July 22, 2024, will combine Pharma Two B's P2B001 Parkinson's Disease treatment candidate with Hepion's liver disease portfolio. The transaction is expected to close in Q4 2024, subject to stockholder approvals and other conditions. A special stockholder meeting is scheduled for December 12, 2024, at 9:00 AM ET via webcast. Upon closing, the combined entity will operate as Pharma Two B and trade under the symbol 'PHTB'.
Pharma Two B and Hepion Pharmaceuticals (Nasdaq: HEPA) have filed a registration statement on Form F-4 with the SEC for their proposed merger. The filing contains a proxy statement/prospectus detailing the transaction announced on July 22, 2024. Pharma Two B, developing P2B001 for Parkinson's Disease, aims to go public on Nasdaq through this merger with Hepion, which has been developing treatments for liver diseases including NASH and HCC.
The merger, approved by both companies' boards, is expected to close in Q4 2024, subject to stockholder and regulatory approvals. Post-merger, the combined entity will operate as Pharma Two B and trade under the ticker symbol "PHTB". The transaction is supported by financial advisors A.G.P./Alliance Global Partners for Hepion and Laidlaw & Company (UK) for Pharma Two B, along with respective legal advisors.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
